Posted by Michael Wonder on 20 Feb 2020
ICER releases draft evidence report on therapies for cystic fibrosis
20 February 2020 - Public comment period now open until 18 March 2020; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for cystic fibrosis. ICER’s report focuses on elexacaftor/tezacaftor/ivacaftor (Trikafta, Vertex).
ICER also examined new data that has become available since its May 2018 review of three other cystic fibrosis treatments already approved by the FDA: tezacaftor/ivacaftor (Symdeko, Vertex), lumacaftor/ivacaftor (Orkambi, Vertex), and ivacaftor (Kalydeco, Vertex).This preliminary draft marks the midpoint of ICER’s eight-month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
